Ascitic complement system in ovarian cancer

L Bjørge*1,2,3, J Hakulinen1, OK Vintermyr4, H Jarva1, TS Jensen2, OE Iversen2 and S Meri1,5

1Department of Bacteriology and Immunology, Haartman Institute, University of Helsinki, FIN-00014 Helsinki, Finland; 2Department of Obstetrics and Gynaecology, N-5021 Haukeland Hospital, University of Bergen, Norway; 3Department of Microbiology and Immunology, The Gade Institute, Haukeland University Hospital, N-5021 Bergen, Norway; 4Department of Pathology, The Gade Institute, Haukeland University Hospital, N-5021 Bergen, Norway; 5Huslab, Helsinki University Central Hospital, FIN-00290 Helsinki, Finland

Ovarian cancer spreads intraperitoneally and forms fluid, whereby the diagnosis and therapy often become delayed. As the complement (C) system may provide a cytotoxic effector arm for both immunological surveillance and mAb-therapy, we have characterised the C system in the intraperitoneal ascitic fluid (AF) from ovarian cancer patients. Most of the AF samples showed alternative and classical pathway haemolytic activity. The levels of C3 and C4 were similar to or in the lower normal range when compared to values in normal sera, respectively. However, elevated levels of C3a and soluble C5b-9 suggested C activation in vivo. Malignant cells isolated from the AF samples had surface deposits of C1q and C3 activation products, but not of C5b-9 (the membrane attack complex; MAC). Activation could have become initiated by anti-tumour cell antibodies that were detected in the AFs and/or by changes on tumour cell surfaces. The lack of MAC was probably due to the expression of C membrane regulators CD46, CD55 and CD59 on the tumour cells. Soluble forms of C1 inhibitor; CD59 and CD46, and the alternative pathway inhibitors factor H and FHL-1 were present in the AF at concentrations higher than in serum samples. Despite the presence of soluble C inhibitors it was possible to use AF as a C source in antibody-initiated killing of ovarian carcinoma cells. These results demonstrate that although the ovarian ascitic C system fails as an effective immunological surveillance mechanism, it could be utilised as an effector mechanism in therapy with intraperitoneally administrated mAbs, especially if the intrinsic C regulators are neutralised.

British Journal of Cancer (2005) 92, 895 – 905. doi:10.1038/sj.bjc.6602334 www.bjcancer.com

Published online 22 February 2005

© 2005 Cancer Research UK

Keywords: ovarian neoplasm; ascitic fluid; complement; immunosurveillance; immunotherapy

Ovarian cancer is the sixth most common malignant neoplasm in women worldwide (Pisani et al., 2002). Despite maximal cytoreductive surgery and chemotherapy regimens, the overall survival rate is still below 40% (Bjørge T et al., 1998). This is mainly due to innate or acquired drug resistance and the fact that the majority of tumours have progressed to an advanced stage at the time of diagnosis (Bjørge T et al., 1998; Baekelandt et al., 2000).

Ovarian carcinomas are the most common primary tumours that lead to the production of free abdominal fluid or ascites (AF) (Zeimet et al., 1998). However, the mechanisms of generation and the role of ascites in the biology of ovarian cancer are widely unknown. Usually, at the time of diagnosis, the cancer has already spread beyond the ovaries, and symptoms related to the presence of free abdominal fluid are often the first manifestation of the disease (Zeimet et al., 1998). Characteristically, the malignant cells often remain confined to the abdominal cavity in direct contact with AF both as peritoneal implants and as free-floating tumour cells, thereby complicating the complete surgical removal of the tumour cells (Zeimet et al., 1998).

The complement (C) system is a major component of innate immunity. It eliminates invading microorganisms, transformed cells and molecular aggregates from tissues and biological fluids (Walport, 2001). Complement activation occurs through three convergent pathways, in which the C components are usually activated by sequential proteolytic cleavages and/or by binding to previously activated components. This results in the release of chemotactic factors and cell-activating anaphylatoxins, deposition of opsonic fragments and formation of the membrane attack complex (MAC) (Walport, 2001). Although C may become activated on tumour cells by tumour-binding antibodies (Magyar- laki et al., 1996), immune complexes (Lucas et al., 1996) or as a consequence of apoptosis (Matsumoto et al., 1997) or proteolytic processes (Niculescu et al., 1992; Yamakawa et al., 1994; Bjørge L et al., 1997a), the cytotoxic activity of C is insufficient as an effective immunological surveillance mechanism against tumours (Gorter and Meri, 1999; Jurianz et al., 1999). Immunotherapy with C-activating mAbs in the treatment of solid tumours has so far shown only limited success (Dillman, 1994; Gruber et al., 1996). The ‘humanised’ anti-CD20 mAb, rituximab has shown an overall response rate of over 50% (Maloney et al., 1997) in the treatment of non-Hodgkin’s lymphomas. This mAb acts by activating C and by causing antibody-dependent cellular cytotoxicity and apoptosis (Golay et al., 2000; Harjunpaa et al., 2000). The limited susceptibility of solid tumour cells to C, can, in part, be explained by the presence of intrinsic cellular C resistance mechanisms and by
limited accessibility of mAbs and C components to the tumours (Bjørge L et al, 1997a; Hakulinen and Meri, 1998; Gorter and Meri, 1999; Jurianz et al, 1999).

Complement resistance of both malignant tumour cells and normal cells is mediated by membrane-bound C regulatory proteins that either limit the formation of the C3/C5 convertase enzymes, or the assembly of the MAC (Morgan and Meri, 1994; Gorter and Meri, 1999; Jurianz et al, 1999; Walport, 2001). The key C enzymes, C3/C5 convertases, are inhibited by the following C regulatory proteins; complement receptor type 1 (CR1, CD35), decay-accelerating factor (DAF, CD55) and membrane cofactor protein (MCP, CD46). These molecules prevent the assembly and promote the decay of the C3/C5 convertase complexes (CR1 and DAF), or serve as cofactors for the plasma serine protease factor 1, which irreversibly inactivates C4b and C3b (CR1 and MCP). Protectin (CD59), on the other hand, inhibits the formation and function of MAC complexes on cell surfaces. In addition, nucleated cells have the capacity to remove MAC-containing membrane particles from their cell surfaces by vesiculation or internalisation (Morgan, 1992). Some tumour cells have also been found to secrete the soluble C regulators factor H (FH) and factor H-like protein 1 (FHL-1) (Junnikkala et al, 2000, 2002).

Antibody responses develop in ovarian cancer, and tumour-reactive immunoglobulins directed both against intracellular proteins and surface antigens have been demonstrated in patient sera (Chinni et al, 1997; Taylor and Gercel-Taylor, 1998; Abendstein et al, 2000; Gercel-Taylor et al, 2001). The antibody levels increase as the disease progresses (Taylor and Gercel-Taylor, 1998). Furthermore, ascitic immunoglobulins of IgM and IgG classes have been described (Silburn et al, 1984a, b; Rao and Hanjani, 1988). They are present either as circulating free antibodies, in immune complexes, or bound to tumour cells and cellular fragments (Silburn et al, 1983; Runowicz et al, 1989; Kawata and Sekiya, 1998; Taylor and Gercel-Taylor, 1998). Despite the fact that they are partially tumour-reactive, they fail to destroy the tumour cells (Taylor and Gercel-Taylor, 1998).

Factors of the C system (Runyon et al, 1985; Mal et al, 1991; Alexandrakis et al, 2001), chemoatractants and opsonic activity (Runyon et al, 1985; Mal et al, 1991) have been described in AF from ovarian cancer patients. The ascitic C system, although incompletely characterised, has been given the role as a protector against spontaneous bacterial peritonitis (Runyon et al, 1985).

In our previous studies, we have described the expression of the C regulators MCP, DAF and CD59 on ovarian carcinoma cells both in solid tumours and in culture (Bjørge L et al, 1997a). DAF and CD59 appeared to be the main factors that protected malignant ovarian cells against C-mediated killing. Furthermore, FH and FHL-1 were found to be produced by ovarian tumour cells, and in solid ovarian tumours FH and FHL-1 were present in the apical tumour cell layers (Junnikkala et al, 2002).

It has been suggested that the AF represents an appropriate environment for studies of tumour biology and locally occurring host–tumour interactions (Zeimet et al, 1998). In the present study, we have investigated the AF C system in ovarian cancer patients to more precisely understand the local humoral anti-tumour immune responses, and to reveal mechanisms whereby the growing tumours escape the host’s innate immune system. As intraperitoneal delivery of mAbs could potentially be used in the treatment of ovarian cancer (Rubin, 1993), the susceptibility of malignant ovarian cells to C-mediated killing with AF as a C source was also examined.

MATERIALS AND METHODS
Collection and storage of AF samples and preparation of ascitic tumour cells

The study was approved by the Regional Ethical Committee of Western Norway (Nnr. 234/97-81.97), and informed consents were obtained from the patients. Ascitic fluid samples were obtained in a prospective, nonselective fashion from patients referred to the Haukeland University Hospital (Bergen, Norway) for the treatment of presumed ovarian cancer. The histopathological diagnoses were obtained according to the 1986 revised staging system of the Fédération International d’Obstétrique (FIGO, 1987), at the Department of Pathology, The Gade Institute, Haukeland University Hospital. Ascitic fluid samples were obtained during laparotomy immediately after the peritoneal cavity was opened and taken into silicone-coated tubes or tubes containing 1 mm EDTA (final concentration). The samples were cooled to 4 °C and transported to the laboratory. The samples from the patients (n = 16) (Table 1) were centrifuged at 1100 × g for 10 min to separate cells and other debris from the fluid phase. The cell-free fluid was aliquoted and stored at −70 °C until used. Samples from

| Patient no. | Age | Diagnosis                      | Stage | Histology                        |
|------------|-----|--------------------------------|-------|----------------------------------|
| 1          | 71  | Ovarian cancer                  | Iib   | Serous cystadenocarcinoma         |
| 2          | 60  | Ovarian cancer                  | Iic   | Serous cystadenocarcinoma         |
| 3          | 75  | Ovarian cancer                  | III   | Serous cystadenocarcinoma         |
| 4          | 30  | Ovarian cancer                  | IIc   | Endometroid adenocarcinoma        |
| 5          | 44  | Ovarian cancer                  | IV    | Papillary serous cystadenocarcinoma |
| 6          | 52  | Ovarian cancer                  | lb    | Endometroid adenocarcinom         |
| 7          | 67  | Ovarian cancer                  | IIc   | Papillary serous cystadenocarcinoma |
| 8          | 59  | Ovarian cancer                  | IIc   | Papillary serous cystadenocarcinoma |
| 9          | 72  | Ovarian cancer                  | IV    | Papillary serous cystadenocarcinoma |
| 10         | 72  | Ovarian cancer                  | IIc   | Papillary serous cystadenocarcinoma |
| 11         | 74  | Ovarian cancer                  | IIc   | Mucinous adenocarcinoma           |
| 12         | 57  | Ovarian cancer                  |       |                                  |
| 13         | 65  | Endometrial cancer              |       |                                  |
| 14         | 56  | Fallopian tube cancer           |       |                                  |
| 15         | 50  | Breast cancer                   |       |                                  |
| 16         | 59  | Cystadenoma in the left ovary   |       |                                  |
| 17         | 68  | Alcoholic liver cirrhosis       |       |                                  |
| 18         | 64  | Chronic active hepatitis (seronegative), liver cirrhosis and hepatorenal syndrome |       |                                  |
two patients with nonmalignant AF were obtained by paracentesis at the Medical Department, Division of Gastroenterology, Haukeland University Hospital, and processed in the same way as the AF from the patients with ovarian tumours.

Tumour cells were isolated from AF samples from two patients (patients no. 2 and 10) by a density gradient separation method. Conically shaped glass tubes (15 ml; Schott Glasswerke, Mainz, Germany) or plastic vials (50 ml; Elkay, Shrewsbury, USA) were used for the preparation of density gradients. The density separation liquid (Lymphoprep solution10; Nycomed, Oslo, Norway) was loaded in three equally sized layers. The bottom layer consisted of Lymphoprep solution (1.077 g ml -1), the middle layer (1.059 g ml -1) of a mixture of 1 vol. Lymphoprep and 0.75 vol. Krebs-Hepes-Ringer (KHR) solution (136.9 mM NaCl, 5.36 mM KCl, 0.34 mM NaH2PO4, 2 mM H2O, 0.35 mM KH2PO4, 0.8 mM MgSO4·7H2O, 1 mM Hepes, pH 7.4) without Ca2+ and Mg2+, and the top layer (1.030 g ml -1) of a mixture of 1 vol. Lymphoprep and 2 vol. of the KHR solution. All density gradient fractions were supplemented with 1 mM EDTA. The AF samples used for cell isolation were prepared from coagulated blood of healthy laboratory personnel and stored at -70 °C until used.

Concentrations of IgM, IgG, C3, C4, C1-inhibitor and factor H in AF

The concentrations of IgM, IgG, C3 and C4 were determined using precipitating antisera in a Nephelometer Analyzer (Behringwerke AG, Marburg, Germany). The C1-inhibitor (C1INH) concentration was determined by radial immunodiffusion (Nor-Partigen; Behringwerke AG). Factor H and FHL-1 concentrations in the AF samples were determined by an enzyme-linked immunosorbent assay (ELISA) as described previously (Junnikkala et al, 2002). Samples of AF were assayed for total protein content using the Bio-Rad Protein Assay (Bio-Rad Laboratories, Hercules, CA, USA) according to the instructions from the manufacturer.

Antibodies and sera

A rat hybridoma cell line (YTH53.1) producing a mAb to human CD59 was originally obtained from Professor H Waldmann (Sir William Dunn School of Pathology, Oxford, UK). YTH53.1 (IgG2b) was purified from cell culture supernatant using a Protein G Sepharose 4 Fast Flow affinity column (Pharmacia BioTech, Uppsala, Sweden). Mouse mAbs to DAF (CD55; BRIC230 and BRIC216; IgG1) and CD59 (BRIC229; IgG2b) were purchased from the International Blood Group Reference Laboratory (IBGRL, Bristol, UK). Murine mAb to human MCP (CD46; J4-48; IgG1) was purchased from Immunotech (Marseille, France) or obtained as a gift (GB24; IgG1) from Drs K Liszewski and JP Atkinson (Washington University School of Medicine, St Louis, MO, USA). Murine mAb to human TCC (aE11; IgG2a) and rabbit polyclonal antibodies to human C1q, C3c, IgG and IgM were all obtained from Dako. Peroxidase-conjugated rabbit immunoglobulins (Igs) to mouse IgG, peroxidase-conjugated-swine Igs to rabbit IgG, peroxidase-conjugated-rabbit Igs to human IgG and peroxidase-conjugated-rabbit Igs to human IgM were purchased from Jackson ImmunoResearch Laboratories (Burlingame, CA, USA). Normal human serum (NHS) that served as a source of C was prepared from coagulated blood of healthy laboratory personnel and stored in aliquots at -70 °C until used.

Cell lines

The human ovarian adenocarcinoma cell lines (Caov-3, SK-OV-3 and SW626), human ovarian teratocarcinoma cell line (PA-1) and human endothelial cell line (HUVEC-C) were all obtained from American Type Culture Collection (ATCC, Manassas, VA, USA). The cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM; Gibco, Paisley, UK) supplemented with 10% heat-inactivated foetal calf serum (FCS; Gibco), 2 mM l-glutamine (Bio Whittaker, Walkersville, MD, USA) and antibiotics (10 U ml -1 of penicillin (AL, Oslo, Norway) and 10 μg ml -1 of streptomycin (Glaxo, Greenford, UK)) at 37 °C in a humidified atmosphere with 5% CO2. Cells were grown in 75 cm2 cell culture flasks (Costar, Cambridge, MA, USA) and subcultured twice a week. Suspensions of the cells were obtained by incubating the cell cultures with Versene/EDTA (Gibco). Thereafter, the cells were washed twice in growth medium and resuspended.

Secreted or shed molecules from the different cell lines were collected in the following way: the cell lines were grown in 75 cm2 cell culture flasks until 90% confluent, washed three times with a cell culture medium containing no FCS, and fresh medium without supplements was added. After a 48-h incubation period, the cell cultures were harvested and centrifuged twice at 500 and 800 g for 10 min, before the supernatants were filtered through ultrafilters with a pore size of 0.45 μm (Minisart®, Sartorius AG, Göttingen, Germany). The samples were further concentrated (100 ×) in Biomax concentrators (Millipore, Bedford, MA, USA) with a cutoff limit of 10 kDa.

Analysis of relative amounts of soluble and membrane forms of CD59 in AF

Ascitic fluid samples and concentrated cell culture supernatants were electrophoresed in 10% SDS–PAGE slab gels under nonreducing conditions. The proteins were transferred onto nitrocellulose filters. After blocking the membranes with 5% nonfat milk powder in phosphate-buffered saline (PBS), pH 7.4 for 30 min, the filters were incubated overnight at 4 °C with mAbs directed against CD46 (J4-48; 0.5 μg ml -1), CD55 (BRIC230 or BRIC216; 0.5 μg ml -1) or CD59 (BRIC229; 0.5 μg ml -1) diluted in PBS containing 5% nonfat milk power. In controls, the primary antibodies were omitted or replaced with an irrelevant antibody of the same subclass as the specific mAb. After washing with PBS, the bound antibodies were visualized using peroxidase-conjugated anti-mouse IgG and a chemiluminescence substrate (SuperSignal ULTRA Substrate; Pierce Chemical Company, Rockford, IL, USA) according to the instructions from the manufacturer.
+ 22°C. Samples of the different phases were analysed by SDS–PAGE and immunoblotting for the presence of CD59 as described above. The aqueous phase contained exclusive CD59 that was fee of attached phospholipids.
a teflon pestle in a glass homogeniser and further incubated for 10 min on ice. After removing the nuclei by centrifugation (twice at 1500 g, 5 min), the cell membranes were pelleted at 20,000 g for 15 min. The membrane pellets were run in SDS–PAGE slab gels (5–15%) under nonreducing conditions and transferred onto nitrocellulose sheets. The strips of the nitrocellulose sheets were incubated with AF samples diluted in PBS (1:800), and the bound IgG was detected with peroxidase-conjugated anti-human IgG and a chemiluminescence detection system.

RESULTS

Immunoglobulins, C components and regulators in AF

All the patients with neoplasms were previously untreated, and all underwent surgery. The clinical characteristics of the patients are summarised in Table 1.

To analyse factors needed in humoral immune responses, we initially measured the concentrations of IgG, IgM and C components in the AF samples (Table 2). The mean concentrations of IgG (8.66 ± 2.58 g l⁻¹) and IgM (0.35 ± 0.12 g l⁻¹) in the ovarian cancer patients’ AFs were lower than the average concentrations in normal human sera, despite the fact that the total protein concentrations in the malignant AFs were 93–140% of the serum values. In comparison, the concentrations of IgG in a patient with alcoholic liver cirrhosis (2.13 g l⁻¹) and in a patient with chronic active hepatitis (2.74 g l⁻¹) were approximately 1/4 of the lower limit measured for NHS (8.0–18.0 g l⁻¹), while the IgM levels in these samples were within the same range as in the malignant AF.

The levels of C3 (0.79 ± 0.25 g l⁻¹) and C4 (0.15 ± 0.05 g l⁻¹) in the AF samples were approximately the same or at the lower limit measured for serum samples (0.5–1.5 and 0.15–0.50 g l⁻¹, respectively). The concentrations of C3 and C4 in the nonmalignant AFs were below the threshold levels of the assays used for the measurements. The C1INH-level (0.21 ± 0.04 g l⁻¹) in malignant AFs was similar to the one present in normal serum (range: 0.21–0.24 g l⁻¹). In contrast to most other parameters, the average combined level of factor H and FHL-1 (0.758 ± 0.312 g l⁻¹) in the AF from ovarian cancer patients was higher than that in NHS (0.461 ± 0.063 g l⁻¹) (Junnikkala et al., 2002). In comparison, the factor H/FHL-1 levels in the liver failure AF samples were very low (0.016 and 0.050 g l⁻¹).

Soluble forms of membrane bound C regulators in AF

Interestingly, in addition to C1INH and factor H/FHL-1, we detected soluble forms of C membrane regulators in AF. By immunoblotting, soluble MCP was detected in AF in seven out of 12 cases with ovarian cancer. The anti-MCP antibody reactive bands (58 and 68 kDa) comigrated with MCP from peripheral blood cells. No MCP was detected in AF from patients suffering from conditions other than ovarian cancer (Table 2).

Unlike MCP, no soluble form of DAF could be detected in any of the samples tested (Table 2), while erythrocyte extracts run in the same setups showed positive staining for DAF at 70 kDa.

A characteristic anti-CD59 reactive smear around 20 kDa was detected in all AF samples tested. A semiquantitative comparison of the amount of CD59 in the AF samples is shown in Table 2. To determine whether CD59 was linked to membrane phospholipids, AF samples from ovarian cancer patients were subjected to partitioning with the TX-114 detergent. As shown in Figure 1, CD59 was detected principally in the detergent phase that contains the membrane-associated form of CD59 (Lehto and Meri, 1993). The approximate relative amounts of CD59 in the aqueous and detergent phases were found to be 20 and 80%, respectively, as judged from the intensities of staining (n = 7). Similar results were obtained when AF samples from the three patients with other gynaecological diseases were examined.
Release of membrane C regulators from cultured ovarian tumour cells

To analyse whether soluble forms of C membrane regulators could originate from tumour cells, we examined concentrated cell culture supernatants from Caov-3, SK-OV-3, PA-1 and SW626 cells by immunoblotting (Figure 2). Our earlier FACS analysis showed expression of MCP and CD59 on all the four cell lines and DAF expression on the Caov-3, SK-OV-3 and SW626 cell lines, but not on the PA-1 cell line (Bjørge L et al, 1997a). Supernatants from Caov-3, PA-1 and SW626 cells showed two bands of 46 and/or 70 kDa that reacted with the anti-CD46 mAb J4-48. No such reactivity was seen in the concentrated SK-OV-3 medium. A 70 kDa band was detected when the SW626 supernatant was stained with the anti-CD55 mAbs BRIC216 and BRIC230. None of the supernatants from the other cell lines showed detectable CD55. The anti-CD59 mAb BRIC229 revealed bands of 21 kDa in the supernatants from all the cell lines. No bands could be detected in the negative control, where the primary antibodies were omitted.

Haemolytic C activity and C activation products in the patients’ AF samples

The median haemolytic activity of the classical C pathway in AF (75 U ml⁻¹) was within the range detected in NHS (50–100 U ml⁻¹) (Table 3). In only three samples, no classical pathway activity was detected (nos. 1, 14 and 16). Alternative pathway haemolytic activity in AF samples (95%) was also similar to values in serum (66–129%) (Table 3). No haemolytic activity of either pathway was detected in the non-neoplastic AFs.

To analyse whether C activation had occurred in the AF samples, the levels of C activation products C3a and SC5b-9 were measured. The data are shown in Table 3. The levels of C3a were clearly elevated (2552 ng ml⁻¹) in the ovarian cancer patient AF samples, as compared to values present in normal sera (26–146 ng ml⁻¹) or in nonmalignant AF samples (240 and 1200 ng ml⁻¹). The same was also the case for levels of SC5b-9 in AF samples. The ELISA measurements showed a mean SC5b-9 concentration of 6772 ng ml⁻¹ in the ovarian tumour AF samples. However, the range was wide (0–20211 ng ml⁻¹; Table 3). No SC5b-9 was detected in samples 7 and 11. In samples from patients with liver failure (nos. 17 and 18), the values were 2493 and 1113 ng ml⁻¹, respectively. In conclusion, C activation to the terminal stage had occurred in most, but not all AF samples from ovarian tumour patients.

Sensitivity of ovarian tumour cells to ascites-mediated cytotoxicity

The cytotoxic C activity in AF was examined by first sensitising ⁵¹Cr-labelled Caov-3 and PA-1 cells with a C-activating and CD59-neutralizing mAb (YTH53.1) and exposing the cells to AF. Normal human serum was used as a control source of C in the cell-killing assay. Maximal killing of Caov-3 and PA-1 cells was obtained by treating them with 1% NP-40 detergent. Both Caov-3 and PA-1 cells showed a weak dose-dependent lysis with NHS and AF in the assay. Typical examples are shown in Figure 3. During a 60 min incubation at +37°C, using saturating concentrations of YTH53.1, approximately 5 and 20% of the PA-1 cells were killed in the presence of 33 and 66% of AF (sample no. 20), respectively (Figure 3). In comparison, when PA-1 cells were subjected to C-mediated killing with NHS as a source of C, 2 and 6% of them became lysed in the presence of 33 and 66% of NHS, respectively. However, when the Caov-3 cell line was examined in the same assay, the tested serum sample showed stronger cytolytic activity than the AF sample (no. 15) (Figure 3). No lysis of Caov-3 and PA-1 cells was detected if YTH53.1 was omitted.

Immunostaining of the ovarian tumour cells for membrane bound C regulators and C deposits

Isolated tumour cells from two patients were examined for C regulators and possible deposits of C components. Decay-accelerating factor was expressed on cells from both patients, although only 57% (sample no. 2) and 78% (sample no. 10) of the tumour cells stained positive for DAF (Figure 4A). All the cells from both patients expressed both MCP and CD59 (Figure 4B and C). Although the intensity of staining was stronger for MCP than for CD59, the staining patterns were similar; both membranous and intracytoplasmic granular staining were seen. In comparison,

| Diagnosis                  | Sample no. | CH100CL (U ml⁻¹) | CH100AP (% normal) | C3a (ng ml⁻¹) | SC5b-9 (ng ml⁻¹) |
|----------------------------|------------|------------------|--------------------|--------------|------------------|
| Ovarian cancer             | 1          | <25              | 35                 | 5100         | 2546             |
|                            | 2          | 40               | 95                 | 2750         | 11996            |
|                            | 3          | 60               | 115                | 1800         | 20211            |
|                            | 4          | 100              | 80                 | 3600         | 18928            |
|                            | 5          | 100              | 100                | 3600         | 12414            |
|                            | 6          | <25              | 95                 | 1500         | 1511             |
|                            | 7          | <25              | 80                 | 1100         | <10              |
|                            | 8          | 100              | 100                | 2000         | 2575             |
|                            | 9          | 140              | 100                | 3000         | 4049             |
|                            | 10         | 90               | 70                 | 1375         | 2955             |
|                            | 11         | 70               | 40                 | 1000         | <10              |
|                            | 12         | 80               | 120                | 3800         | 4067             |
| Mean ± s.d.                | 68.13 ± 41.53 | 85.83 ± 26.61     | 2552 ± 1292        | 6772 ± 7208  |

| Other gynaecological neoplasms | 13 | 70 | 65 | 2750 | <10 |
|                                 | 14 | <25 | 50 | 6300 | 2946 |
|                                 | 15 | 90 | 60 | 7300 | 12659 |
|                                 | 16 | <25 | 65 | 3500 | 12307 |
| Liver failure                   | 17 | <25 | — | 240 | 2493 |
|                                 | 18 | <25 | — | 1200 | 1133 |
| Serum/range                     | 50–100 | 66–129 | 26–146 | <100 |
In principle, C activation in AF against ovarian cancer cells could become initiated by antitumour antibodies in the AF. Specific IgG responses in patients’ AF against ovarian cancer cell antigens

In principle, C activation in AF against ovarian cancer cells could have become initiated by antitumour antibodies in the AF. Therefore, we studied whether the cancer patients’ AF contained IgG that would bind to ovarian tumour cell antigens. The membranes of Caov-3, PA-1, SK-OV-3 and SW626 cells were isolated, electrophoresed in 5–15% SDS-PAGE slab gels, blotted onto nitrocellulose filters and probed with dilutions of the AF samples. Immunoglobulins in the AF samples from the ovarian cancer patients reacted with several cell membrane antigens. IgG in the AF sample no. 11 reacted with a 25 kDa antigen in Caov-3, PA-1 and SK-OV-3 cell membranes. The AF sample no. 13 reacted with a 55 kDa antigen in Caov-3, PA-1 and SK-OV-3 cell membranes. The IgG in the AF sample no. 21 reacted with a 70 kDa antigen in Caov-3, PA-1 and SK-OV-3 cell membranes. In addition, IgG from six patients (nos. 13, 14, 19, 20, 23 and 24) detected a 48 kDa antigen in PA-1 cells (Figure 6). In contrast, IgG in the AFs from the control patients with liver failure did not detect any antigens from the Caov-3, PA-1 or SK-OV-3 cell membranes.

**DISCUSSION**

In this study, we have observed tumour-reactive antibodies of the IgG class, and a functionally active C system in the AF of most of the examined patients with ovarian cancer. High levels of C activation products in the AF samples and deposits of C1q and C3 on the isolated tumour cells indicate that the AF C system has become activated in vivo. The tumour cells expressed membrane bound C regulators on their surfaces and secreted their soluble forms, as well as other soluble C inhibitors into their local environment. These inhibitors are likely to restrict the cytotoxic activity of AF against tumour cells. Our results suggest that although the ovarian tumour cells in the malignant AF fluids are surrounded by a functional C system, they are protected against C activation. The tumour cells have C inhibitors on their cell membranes and may also create a microenvironment where fluid phase C activation is regulated. Therefore, if the ovarian tumour cells are to be killed by tumour-specific mAbs and AF C, their intrinsic C resistance, at least in part, must be overcome. This could be achieved, in principle, with specific C regulator neutralising antibodies.

The protein concentrations in malignant ovarian cancer AF samples were 94–140% of those in serum, while the protein levels in nonmalignant AFs were only 11–13.5% of serum values. These data are similar to those reported earlier by others, and illustrate the exudate and transudate natures of malignant and nonmalignant AFs, respectively (Parsons et al, 1996). The substantially high protein content in malignant AF is likely due to an increased permeability of small blood vessels, release and shedding of proteins from tumour cells, inflammatory and mesothelial cells (Parsons et al, 1996), while the nonmalignant AF is a pure transudate.

The antibodies of the IgG and IgM classes were present in malignant patients’ AF at median concentrations of 8.12 and 0.33 g l\(^{-1}\), respectively. IgM and IgG in AF might be derived both from plasma cells and plasma cells (Nakamura et al, 1978). As shown in Figure 5, some of the AF IgG bound to distinct surface structures on the ovarian cancer cells. The responses seemed to be individual as no specific uniform binding pattern profile could be obtained for the patient group as a whole. Antibodies present in the AF could act as activators of the C system.

A functionally active C system was detected in the AF of patients with ovarian cancer. In line with earlier studies (Runyon et al, 1985; Mal et al, 1991), the amounts of C3 and C4 were comparable to those present in NHS. Both factors can be produced locally by inflammatory and epithelial cells. To our knowledge this is the first study examining the cytotoxic activity of C in malignant AF. Our

---

**Figure 3** Complement-mediated lysis of PA-1 and Caov-3 cells with ascitic fluids from ovarian cancer patients. Caov-3 and PA-1 cells were labelled with \(^{51}\)Cr. After sensitising with the anti-CD59 C-activating mAb (YTH53.1; 350\(\mu\)g ml\(^{-1}\)), the cells were exposed to ascites fluid (○) or normal human serum (C). The AF and serum dilutions are indicated on the x-axis. The released radioactivity was counted from the supernatants after a 30 min incubation at 37°C. Cell lysis was determined as a percentage of the maximum releasable radioactivity: \(((\text{released radioactivity–spontaneous release})/(\text{maximum released radioactivity–spontaneous release})) \times 100\%\).
results show that a functionally active C system is present in the AF. Classical and alternative pathway haemolytic activities were seen in nine out of 12 and 12 out of 12 of the malignant AFs, respectively. For most positive samples, the activity was at the level of that present in NHS. In comparison, no such activity could be found in the nonmalignant AF samples.

The presence of soluble C3a and SC5b-9 showed that the C system in AF had become activated in vivo in many of the patients. The concentrations of C3a and SC5b-9 were much higher in patients with a neoplastic disease than in patients with liver failure. Furthermore, on isolated tumour cells deposits of C1q and C3d, but not of C5b-9, could be detected. This is an original observation, and one of the first reports to show C deposition on tumour cells in vivo. Complement activation may be due to classical pathway activation initiated directly by membrane-bound antibodies or indirectly by immune complexes in the AF. Immune complex-induced C activation may lead to a bystander attack against adjacent cells. Alternatively, activation may have occurred by antibody-independent mechanisms, either via the alternative pathway, or via a direct interaction of C1q with exposed cell constituents like perturbed cellular or mitochondrial membranes or chromatin. Tumour cells that have become detached from their original sites may undergo apoptotic (or necrotic) changes and expose binding sites for C1q. This together with a reduced ability to control C could lead to C activation.

To examine whether C in AF could kill viable tumour cells, we tested the cytotoxic activity of the AF samples in a targeted C-mediated killing assay. Different combinations of ovarian tumour cell lines and AF samples were tested. By using a specific C-activating mAb against the cell surface CD59-antigen (YTH53.1; IgG2b), we found that it was possible to use the AF as a cytotoxic C source. For most of the AF samples examined, the cytotoxic activities were weaker than in the NHS samples tested for comparison.

To investigate whether the tumour cells’ relative resistance to C could be due to the expression of membrane regulators CD46, CD55 and CD59, we performed immunohistochemical analysis of tumour cells isolated from two patients with ovarian cancer. As shown in Figure 4, MCP and CD59 were strongly expressed on all the isolated tumour cells (B and C), while DAF expression was weaker and more heterogeneous (A).

Figure 4 Immunohistochemical analysis of the expression of membrane bound C regulators on ovarian tumour cells isolated from AF. Cytotospin specimens were fixed and stained with the mAbs BRIC 216 (A), J4-48 (B) and BRIC 229 (C) directed against DAF, MCP and CD59, respectively. An irrelevant mouse IgG was used as a negative control (D). The bound mAbs were detected using an immunoperoxidase staining kit. Original magnification, × 200. Membrane cofactor protein and CD59 were strongly expressed by all the isolated tumour cells (B and C), while DAF expression was weaker and more heterogeneous (A).

We have previously shown that the amounts of alternative pathway inhibitors FH/FHL-1 are higher in AF samples than in sera (Junnikkala et al, 2002). The concentrations of FH/FHL-1 in AF were relatively high (Table 2); nearly twice of those in sera. We have observed that it is specifically the concentration of FHL-1 that is high in AF, and that functionally active FH and FHL-1 molecules are synthesised by the ovarian tumour cells (Junnikkala et al, 2002). The small FHL-1 molecule may thus act as
a 'quick-response' protective molecule to suppress C activation. Released soluble MCP may also have a similar, although a weaker activity in the AF.

The amount of cell-free CD59 was found to be higher in AF than in sera and in AF from patients with liver cirrhosis (Table 2). We have shown earlier that ovarian and breast tumours of various
histological types all express high levels of CD59 (Hakulinen and Meri, 1994; Bjørge L et al, 1997a). The AF samples were obtained from patients with a big tumour burden. The observation that AF from patients with other large-sized gynaecological tumours of different histological types (both malignant and benign) also contained high levels of CD59 suggests that the release of CD59 from cells is related to tumour mass rather than to the malignancy itself.

The full inhibitory activity of CD59 requires the presence of an intact phospholipid tail that can incorporate into lipid bilayers. Using a Triton X-114 phase separation method, an average of 80% of AF CD59 was found to represent a form with anchor-associated phospholipid. Similarly, phospholipid-tailed CD59 has been found principally in amniotic fluid (Rooney and Morgan, 1992), seminal plasma (Rooney et al, 1993) and in milk (Hakulinen and Meri, 1995). A proportion of CD59 may also be shed in small membrane vesicles. The presence of a high level of phospholipid-containing CD59 may in part explain the results of the functional analysis showing that AF in general has a weaker C activity than NHS.

The presence of soluble forms of C membrane regulators in AF is assumed to be due to release from tumour cells. The immunoblotting experiments showed that the cultured ovarian cancer cells can shed the C regulators CD46, CD55 and CD59 into the culture medium. There is evidence that this is also the case with tumours derived from other tissues (Bjørge L et al, 1994, 1996; Jurianz et al, 1999; Hakulinen et al, 2004). It is likely that the C regulators in AF, at least in part, are derived from the tumours themselves. The secretion of both soluble C regulators, like FH/ FIH-1, and the release of membrane regulators can thus provide additional resistance to ovarian tumours in the AF or at least restrict the activity of the C system within the AF.

The presence of C activators and a functional C system in malignant AF suggests that C attack against tumour cells represents a partially operative immunological surveillance mechanism. We have, however, shown that the AF C system has an insufficient capacity to mediate effective C-mediated tumour cell killing. The expression of membrane bound C regulators on tumour cells and the release of C regulators may at least partly explain the resistance. In addition, aggregated malignant cells are more difficult to kill by C than single cells (Bjørge L et al, 1997b; Hakulinen and Meri, 1998), further contributing to the tumour escape.

Recently, Ng et al (2002) have reported that the intraperitoneal injection of the C activating mAb rituximab is an effective measure to control recurrent abdominal ascites in non-Hodgkin’s lymphoma. In the case of ovarian cancer, the presence of tumour cells within the peritoneal cavity surrounded by a functional C system also makes this tumour type an attractive target for local monoclonal antibody therapy (Markman, 1998). Although clinical trials so far have failed to lead to any consistent response pattern, it is possible that such therapy could be of considerable benefit. Soluble as well as membrane regulators of C restrict tumour cell lysis. However, the tumor cell killing by mAbs could be improved if the activity of the C system within the peritoneal space can be enhanced and the sensitivity of the tumour cells increased, for example, by temporarily blocking C inhibitors. As shown in the present study, the AF with its active C system could provide effector mechanisms for mAb-mediated therapy of ovarian tumours.

ACKNOWLEDGEMENTS

We gratefully acknowledge grants from The Academy of Finland, The Finnish Cancer Society, The Finnish Cultural Foundation, The Helsinki University Central Hospital Funds, Lillemor Grobstock Foundation, The Norwegian Cancer Society, Norske Kvinner Sanitets Forening, The University of Helsinki and The Sigrid Jusélius Foundation. We thank Bente Heggo Hansen, Britt Edvardsen and Marjatta Ahonen for excellent technical assistance and Professor Arnold Berstad, Department of Internal Medicine, Haukeland University Hospital, for providing nonmalignant AF samples.

REFERENCES

Abendstein B, Marth C, Muller-Holzner E, Widschwendter M, Daxenbichler G, Zeimet AG (2000) Clinical significance of serum and ascitic p53 autoantibodies in epithelial ovarian carcinoma. Cancer 88: 1342 – 1437
Alexandrakis MG, Kyriakou D, Koutroubakis IE, Alexandraki R, Vlachonikolis IG, Eliopoulos GD (2001) Assaying of tumour necrosis factor alpha, complement factors, and alpha-1-antitrypsin in the diagnosis of malignant serous effusions. Am J Clin Oncol 24: 562 – 566
Bækelandt MM, Holm R, Nesland JM, Trope CG, Kristensen GB (2000) P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer. Anticancer Res 20: 1061 – 1067
Bjørge L, Hakulinen J, Wahlstrøm T, Matre R, Meri S (1997a) Complement-regulatory proteins in ovarian malignancies. Int J Cancer 70: 14 – 25
Bjørge L, Jensen TS, Matre R (1996) Characterisation of the complement-regulatory proteins decay-accelerating factor (DAF, CD55) and membrane cofactor protein (MCP, CD46) on a human colonic adenocarcinoma cell line. Cancer Immunol Immunother 42: 185 – 192
Bjørge L, Jannikka S, Kristoffersen EK, Hakulinen J, Matre R, Meri S (1997b) Resistance of ovarian teratocarcinoma cell spheroids to complement-mediated lysis. Br J Cancer 75: 1247 – 1253
Bjørge L, Vedeler CA, Ulvestad E, Matre R (1994) Expression and function of CD59 on colonic adenocarcinoma cells. Eur J Immunol 24: 1597 – 1603
Bjørge T, Engelund A, Hansen S, Trope CG (1998) Prognosis of patients with ovarian cancer and borderline tumours diagnosed in Norway between 1954 and 1993. Int J Cancer 75: 663 – 670
Chinni SR, Falchetto R, Gercel-Taylor C, Shabanowitz J, Hunt DF, Taylor DD (1997) Humoral immune responses to cathepsin D and glucose-regulated protein 78 in ovarian cancer patients. Clin Cancer Res 3: 1557 – 1564
Dillman RO (1994) Antibodies as cytotoxic therapy. J Clin Oncol 12: 1497 – 1515
Figg WJ (1987) International Federation of Gynecology and Obstetrics. Changes in definition of clinical staging of the cervix and ovary. Am J Obstet Gynecol 156: 263 – 264
Fleuren GJ, Gorter A, Kuppen PJ, Livinov S, Warnaar SO (1995) Tumour heterogeneity and immunotherapy of cancer. Immunol Rev 145: 91 – 122
Gercel-Taylor C, Bazzett LB, Taylor DD (2001) Presence of aberrant tumour-reactive immunoglobulins in the circulation of patients with ovarian cancer. Gynecol Oncol 81: 71 – 76
Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, Tedesco F, Rambaldi A, Introna M (2000) Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro. CD55 and CD59 complement regulatory-mediated cell lysis. Blood 95: 3900 – 3908
Gorter A, Meri S (1999) Immune evasion of tumour cells using membrane-bound complement regulatory proteins. Immunol Today 20: 576 – 582
Gruber R, Holz E, Riethmuller G (1996) Monoclonal antibodies in cancer therapy. Springer Semin Immunopathol 18: 243 – 251
Guzman J, Hilgarth M, Bross KJ, Wiehle U, Ross A, Kresin V, Costabel U (1988) Lymphocyte subpopulations in malignant ascites of serous papillary ovarian adenocarcinoma. An immunocytochemical study. Acta Cytol 32: 811 – 815
Hakulinen J, Jannikka S, Sorsa T, Meri S (2004) Complement inhibitor membrane cofactor protein (MCP; CD46) is constitutively shed from cancer cell membranes in vesicles and converted by a metalloproteinase to a functionally active soluble form. Eur J Immunol 34: 2620 – 2629
Hakulinen J, Meri S (1994) Expression and function of the complement membrane attack complex inhibitor protectin (CD59) on human breast cancer cells. Lab Invest 71: 820 – 827
Hakulinen J, Meri S (1995) Shedding and enrichment of the glycolipid-anchored complement lysis inhibitor protectin (CD59) into milk fat globules. Immunology 85: 495 – 501
